Get an alert when ASTELLAS ENGINEERED SMALL MOLECULES U.K. LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Next accounts due

2026-12-31 (in 7mo)

Last filed for 2025-03-31

Confirmation statement due

2026-11-19 (in 6mo)

Last made up 2025-11-05

Watchouts

None on the register

Cash

Latest balance sheet

Net assets

£12M

+46.1% vs 2024

Employees

20

+5.3% vs 2024

Profit before tax

-£8M

+12.5% vs 2024

Name history

Renamed 2 times since incorporation

  1. ASTELLAS ENGINEERED SMALL MOLECULES U.K. LIMITED 2024-04-03 → present
  2. NANNA THERAPEUTICS LIMITED 2018-08-14 → 2024-04-03
  3. BACTEVO LIMITED 2012-12-12 → 2018-08-14

Accounts

2-year trend · latest reflected 2025-03-31

Metric Trend 2024-03-312025-03-31
Turnover
Operating profit -£9,570,903-£8,873,685
Profit before tax -£9,062,142-£7,931,926
Net profit -£6,683,939-£6,221,216
Cash -£14,896
Total assets less current liabilities £8,200,282£12,005,244
Net assets £8,189,246£11,968,030
Equity £8,189,246£11,968,030
Average employees 1920
Wages £1,610,566£1,743,311

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2024-03-312025-03-31
Return on capital employed -116.7%-73.9%
Gearing (liabilities / total assets) 21.3%16.3%
Current ratio 3.69x5.25x
Interest cover -353.00x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis
FRS 102
Reporting scope
Standalone (parent only)
Abridged
Yes — abridged accounts (limited disclosure)
Auditor
Ernst & Young
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“The financial statements have been prepared on a going concern basis as a result of a letter of support from an intermediate parent company, Astellas B.V.. After making due enquiries, including consideration of the letter of support received, the Directors of the Company confirm that they have a reasonable expectation that the Company has adequate resources to continue in operational existence for a period of twelve months from the date of approval of these financial statements.”

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

2 active · 8 resigned

Name Role Appointed Born Nationality
BARRETT, David, Dr Director 2022-08-24 Jan 1962 British
FLOWERDEW, Lesley Ann Director 2020-04-18 Oct 1967 British
Show 8 resigned officers
Name Role Appointed Resigned
BULLOCK, Timothy Charles Director 2013-03-22 2017-12-24
GEORGE, Ian Michael Riorden, Dr Director 2013-03-22 2018-01-22
IWAI, Akihiko Director 2020-04-18 2021-03-31
REGGIANI, Ernesto Giorgio Director 2012-12-12 2018-02-08
SHITAKA, Yoshitsugu, Mr. Director 2021-09-13 2022-08-24
THOMPSON, Nicola, Dr Director 2019-06-17 2020-04-18
WAIN, John Richard Director 2013-03-22 2020-04-18
WILLIAMS, David Hugh, Dr Director 2012-12-12 2021-10-15

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Astellas Pharma Europe Ltd. Corporate entity Shares 75–100%, Voting 75–100%, Appoints directors 2020-04-18 Active
New Wave Ventures Llp Legal person Shares 50–75%, Voting 25–50% 2016-04-06 Ceased 2018-03-22

Filing timeline

Last 20 of 94 total filings

Material constitutional events — rename, articles re-file, resolution

  • 2024-04-13 RESOLUTIONS Resolution
  • 2024-04-03 CERTNM Certificate change of name company PDF
Date Type Category Description
2026-01-28 CS01 confirmation-statement Confirmation statement with updates PDF
2026-01-28 RP01AP01 officers Replacement filing of director appointment with name PDF
2025-10-09 AA accounts Accounts with accounts type full
2025-01-28 SH01 capital Capital allotment shares PDF
2024-12-30 AA accounts Accounts with accounts type full
2024-11-20 RP04CS01 confirmation-statement Second filing of confirmation statement with made up date PDF
2024-11-15 CS01 confirmation-statement Confirmation statement with no updates
2024-10-01 RP04SH01 capital Second filing capital allotment shares PDF
2024-09-30 SH01 capital Capital allotment shares PDF
2024-09-29 RP04SH01 capital Second filing capital allotment shares PDF
2024-09-29 RP04SH01 capital Second filing capital allotment shares PDF
2024-09-29 RP04SH01 capital Second filing capital allotment shares PDF
2024-09-28 RP04SH01 capital Second filing capital allotment shares PDF
2024-07-08 AAMD accounts Accounts amended with accounts type full
2024-07-08 AAMD accounts Accounts amended with accounts type full
2024-07-08 AAMD accounts Accounts amended with accounts type full
2024-04-13 RESOLUTIONS resolution Resolution
2024-04-03 CERTNM change-of-name Certificate change of name company PDF
2024-02-17 RP04SH01 capital Second filing capital allotment shares PDF
2023-11-28 SH01 capital Capital allotment shares

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
3

last 12 months

Capital events
7

last 24 months

Officers appointed
0

last 12 months

Officers resigned
0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2024 → FY2025 · period ending 2025-03-31 vs 2024-03-31

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Official Companies House page